About: Prognostic importance of pretransplant disease status for posttransplant outcomes in patients with adult T cell leukemia/lymphoma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Prognostic importance of pretransplant disease status for posttransplant outcomes in patients with adult T cell leukemia/lymphoma Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Prognostic importance of pretransplant disease status for posttransplant outcomes in patients with adult T cell leukemia/lymphoma
Creator	Kim, Sung-Won Inoue, Yoshitaka Fukuda, Takahiro Fuji, Shigeo Inamoto, Yoshihiro Ito, Ayumu Kurosawa, Saiko Nakagama, Hitoshi Okinaka, Keiji Tanaka, • Tanosaki, Ryuji
Source	PMC
abstract	Adult T cell leukemia/lymphoma (ATL) is an aggressive T cell lymphoma with a poor prognosis. Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) can be a curative treatment for ATL, a significant proportion of allo-HSCT recipients suffer from relapse/progression of ATL. Here we aimed to clarify the risk factors for and outcomes after posttransplant relapse/progression. We retrospectively reviewed 76 patients with ATL who received allo-HSCT at our institute. At the time of allo-HSCT, disease status was complete response in 17 patients, partial response in 29, stable disease (SD) in 18, and progressive disease (PD) in 12. In multivariate analysis, SD/PD at allo-HSCT, lymphoma subtype, reduced-intensity conditioning regimen, and time from diagnosis to allo-HSCT were associated with risk of relapse/progression. After allo-HSCT, 26 patients had relapse/progression at a median of 66 days (range, 13–2064 days). The 2-year overall survival rate after relapse/progression was only 19%. Compared with acute-type, lymphoma-type experienced local recurrence more frequently (1/15 acute vs. 7/11 lymphoma, P < 0.01) and had a significantly longer OS after relapse/progression (median; 112 days in acute vs. 554 days in lymphoma, P < 0.01). Since the prognosis of patients with ATL who experienced relapse/progression after allo-HSCT was poor, strategies to reduce the risk of these outcomes are warranted.
has issue date	2018-03-09(xsd:dateTime)
bibo:doi	10.1038/s41409-018-0139-z
bibo:pmid	29523883
has license	no-cc
sha1sum (hex)	fd9a0a05f23e226e536cdbd647a87d128c5f52da
schema:url	https://doi.org/10.1038/s41409-018-0139-z
resource representing a document's title	Prognostic importance of pretransplant disease status for posttransplant outcomes in patients with adult T cell leukemia/lymphoma
has PubMed Central identifier	PMC7102069
has PubMed identifier	29523883
schema:publication	Bone Marrow Transplant
resource representing a document's body	covid:fd9a0a05f23e226e536cdbd647a87d128c5f52da#body_text
is schema:about of	named entity 'ATL' named entity 'reduce' named entity 'relapse' named entity 'survival rate' named entity 'patients' named entity 'YEAR' named entity 'CONDITIONING REGIMEN' named entity 'SUBTYPE' named entity 'CLARIFY' named entity 'SIGNIFICANT' named entity 'PROGNOSIS' named entity 'ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION' named entity 'RISK FACTORS' named entity 'HERE' named entity 'DIAGNOSIS' named entity 'PARTIAL RESPONSE' named entity 'risk' named entity 'T cell' named entity 'lymphoma' named entity 'median' named entity 'progression' named entity 'leukemia' named entity 'progressive disease' named entity 'patients' named entity 'ATL' named entity 'ATL' named entity 'progression' named entity 'risk' named entity 'relapse' named entity 'lymphoma' named entity 'complete response' named entity 'progressive disease' named entity 'relapse' named entity 'prognosis' named entity 'lymphoma' named entity '0.01' named entity 'relapse' named entity 'HSCT' named entity 'survival rate' named entity 'relapse' named entity 'lymphoma' named entity 'lymphoma' named entity 'lymphoma' named entity 'lymphoma' named entity 'HSCT' named entity 'HSCT' named entity 'cyclosporine' named entity 'Flu' named entity '0.49' named entity 'HSCT' named entity 'Flu' named entity 'relapse' named entity 'lymphocytes' named entity 'HSCT' named entity 'lymphoma' named entity 'log-rank test' named entity 'radiation therapy' named entity 'busulfan' named entity 'Flu' named entity 'infection' named entity 'relapse' named entity 'cumulative incidence' named entity 'immunosuppression' named entity 'lymphocyte' named entity 'standard treatment' named entity 'HSCT' named entity 'HSCT' named entity 'lymphoma' named entity 'chemotherapy' named entity 'total body irradiation' named entity 'clinical outcomes'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software